Unique sensory responses to the pediatric HIV medication Kaletra

December 13, 2017

PHILADELPHIA (Dec. 13, 2017) - Bad taste can lead to rejection of life-saving medicines by infants and young children, who require liquid formulations because they are unable to swallow pills yet lack the language to explain why something does not taste good. Seeking to understand why some infants strongly reject Kaletra™, a medication commonly administered as part of the first-line treatment for HIV, while others readily accept it, a recent study from the Monell Center and the Children's Hospital of Philadelphia used a trained adult sensory panel to examine individual differences in the sensory response to the medication. The findings documented a wide range of individual differences in the taste of Kaletra and identified genetic sources of the taste variation.

"The expectation that a given pharmaceutical should taste good to everyone fails to recognize the highly personal nature of taste," said study lead author Julie Mennella, PhD, a developmental psychobiologist at Monell.

The World Health Organization estimates that half of pediatric patients do not take their medicines correctly in part because of the lack of child-friendly, "good-tasting" formulations. Taste can impede medication adherence in infants and young children, who are unable to swallow pills coated to mask offending qualities. At the same time, not all infants and children respond to a given medication in the same way. In the case of Kaletra, some readily accept and swallow the life-saving medication when tasting it for the first time while others forcefully reject it, thereby negating Kaletra's anti-retroviral effectiveness.

To explore the extent of variation in how individuals perceive the taste of liquid Kaletra, which contains the active drugs lopinavir and ritonavir along with inactive ingredients, the researchers used a trained sensory panel of adult women in a proof-of-concept approach.

The findings, published in Clinical Therapeutics, revealed that individual adults responded very differently to the taste of Kaletra. Reflecting the wide range of responses of infants in clinical care, the panelists' ratings for Kaletra's palatability ranged from 'moderate like' to 'strongest imaginable dislike'. The more the medicine tasted bitter to or irritated the mouth of a panelist, the more that panelist disliked the taste.

The wide variation in the palatability and bitterness of the medicine could in part be explained by variation in panelists' taste receptor genes.

In the study, 84 adult trained panelists rated their liking for Kaletra and other ingredients contained in the formulation including sucrose, sodium chloride, and ethanol. They also rated the strength of each specific taste quality (sweet, sour, salty, bitter, savory) and irritation. Panelists tasted each stimulus for 5 seconds and did not swallow. A subset of the panelists were retested several months later to establish that the sensory ratings were stable over time. Each participant also provided saliva, which was used to identify person-to-person variation in genes that determine the structure and function of several taste receptors.

Moving forward, the researchers plan to develop methods to measure taste responses in pediatric patients when tasting Kaletra and other medicines for the first time. The ultimate goal is to broaden the focus of precision medicine to include measures of taste, thereby identifying children who are unlikely to tolerate the taste of a given medicine. "In this age of personalized medicine, the growing field of pharmacogenetics needs to assess how our genes affect how a given medicine tastes to that unique child," said Mennella. "No matter how powerful, a drug cannot be effective if a child does not take it."
-end-
Also contributing to the research was Dr. Elizabeth Lowenthal of the University of Pennsylvania Perelman School of Medicine and Phoebe Mathew of Monell. Research reported in the publication was supported by grants DC011287 and P30DC011735 from the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The Monell Chemical Senses Center is an independent nonprofit basic research institute based in Philadelphia, Pennsylvania. Poised to celebrate its 50th anniversary in 2018, Monell advances scientific understanding of the mechanisms and functions of taste and smell to benefit human health and well-being. Using an interdisciplinary approach, scientists collaborate in the programmatic areas of sensation and perception; neuroscience and molecular biology; environmental and occupational health; nutrition and appetite; health and well-being; development, aging and regeneration; and chemical ecology and communication. For more information about Monell, visit http://www.monell.org.

Monell Chemical Senses Center

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.